A retrospective evaluation of adherence to guidelines for prevention of thromboembolic events in general medical inpatients

Canadian Journal of Hospital Pharmacy

Volumn 59, Issue 5, 2006, Pages 258-263

  Patel, Kaleena ^a,b   Loewen, Peter ^a,c   Wilbur, Kerry ^a  

^a VANCOUVER COASTAL HEALTH   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Medical patients; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; COMPRESSION THERAPY; CONTROLLED STUDY; DRUG CONTRAINDICATION; FEMALE; GENERAL PRACTICE; HOSPITAL PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRACTICE GUIDELINE; PROTECTIVE CLOTHING; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOSIS PREVENTION; UNIVERSITY HOSPITAL; VENOUS THROMBOEMBOLISM;

EID: 34548280389     PISSN: 00084123     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):338S-400S.
2. Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162:1245-8.
3. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991;302:709-11.
4. Sandier DA, Martin JE Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989;82(4):203-5.
5. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874-9.
6. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793-800.
7. Atria J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH. Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 2001;161:1268-79.
8. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-8.
9. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107(23 Suppl 1):19-16.
10. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000;160:3415-20.
11. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004;164:963-8.
12. Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost 2004;2:2156-61.
13. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, et al. Prevention of venous thromboembolism. Chest 2001;119(1 Suppl):132S-75S.
14. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):311S-37S.
15. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):287S-310S.
16. Compendium of pharmaceuticals and specialties. Ottawa (ON): Canadian Pharmacists Association; 2003.
17. Tapson VF. The evolution and impact of the American College of Chest Physicians consensus statement on antithrombotic therapy. Clin Chest Med 2003;24(1):139-51, vii.
18. Arnold DM, Kahn SR, Shrier I. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest 2001;120:1964-71.
19. Stinnett JM, Pendleton R, Skordos L, Wheeler M, Rodgers GM. Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates. Am J Hematol 2005; 78:167-72.
20. Stark JE, Kilzer WJ. Venous thromboembolic prophylaxis in hospitalized medical patients. Ann Pharmacother 2004;38:36-40.
21. Aujesky D, Guignard E, Pannatier A, Cornuz J. Pharmacological thromboembolic prophylaxis in a medical ward: room for improvement. J Gen Intern Med 2002;17:788-91.
22. Ageno W, Squizzato A, Ambrosini F, Dentali F, Marchesi C, Mera V, et al. Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologic 2002;87:746-50.